Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015 (2015), Article ID 792968, 10 pages
http://dx.doi.org/10.1155/2015/792968
Research Article

Psoriasis and Diabetes: A Multicenter Study in 222078 Type 2 Diabetes Patients Reveals High Levels of Depression

1Institute of Epidemiology and Medical Biometry, Central Institute for Biomedical Technology, German Center for Diabetes Research (DZD), University of Ulm, Albert-Einstein-Allee 41, 89081 Ulm, Germany
2Division of Endocrinology & Metabolism, Department of Internal Medicine I, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
3Medical Clinic, Health Center Spaichingen, Diabetes Center, Hospital District Tuttlingen, Robert Koch Straße 31, 78549 Spaichingen, Germany
42nd Department of Internal Medicine, General Hospital Linz, Krankenhausstraße 9, 4021 Linz, Austria
5Department of Internal Medicine, Academic Hospital Paul Gerhardt Stift, Martin Luther University of Halle-Wittenberg, Paul-Gerhardt-Straße 42-45, 06886 Lutherstadt Wittenberg, Germany
62nd Department of Internal Medicine, Clinical Center HELIOS Hildesheim, Senator-Braun-Allee 33, 31135 Hildesheim, Germany
7Department of Diabetes, Clinical Center Dortmund GmbH, Beurhausstraße 40, 44137 Dortmund, Germany
8Department of General Internal Medicine, Endocrinology and Diabetes, HELIOS Clinic Schwerin, Wismarsche Straße 393-397, 19049 Schwerin, Germany

Received 15 April 2015; Revised 1 July 2015; Accepted 22 July 2015

Academic Editor: Mitsuhiko Noda

Copyright © 2015 Anke Schwandt et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. International Diabetes Federation (IDF), Diabetes Atlas, 6th edition, 2014, http://www.idf.org/diabetesatlas.
  2. U. Khalid, P. R. Hansen, G. H. Gislason et al., “Psoriasis and new-onset diabetes: a Danish nationwide cohort study,” Diabetes Care, vol. 36, no. 8, pp. 2402–2407, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. R. S. Azfar, N. M. Seminara, D. B. Shin, A. B. Troxel, D. J. Margolis, and J. M. Gelfand, “Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis,” Archives of Dermatology, vol. 148, no. 9, pp. 995–1000, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Armesto, J. Santos-Juanes, C. Galache-Osuna, P. Martinez-Camblor, E. Coto, and P. Coto-Segura, “Psoriasis and type 2 diabetes risk among psoriatic patients in a Spanish population,” Australasian Journal of Dermatology, vol. 53, no. 2, pp. 128–130, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. A. W. Armstrong, C. T. Harskamp, and E. J. Armstrong, “Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis,” JAMA Dermatology, vol. 149, no. 1, pp. 84–91, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Christophers, “Psoriasis—epidemiology and clinical spectrum,” Clinical and Experimental Dermatology, vol. 26, no. 4, pp. 314–320, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Augustin, C. Spehr, M. A. Radtke et al., “German psoriasis registry PsoBest: objectives, methodology and baseline data,” Journal der Deutschen Dermatologischen Gesellschaft, vol. 12, no. 1, pp. 48–57, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. W.-H. Boehncke and S. Boehncke, “More than skin-deep: the many dimensions of the psoriatic disease,” Swiss Medical Weekly, vol. 144, Article ID w13968, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Ž. Palijan, D. Kovačević, E. Koić, K. Ružić, and F. Dervinja, “The impact of psoriasis on the quality of life and psychological characteristics of persons suffering from psoriasis,” Collegium Antropologicum, vol. 35, supplement 2, pp. 81–85, 2011. View at Google Scholar · View at Scopus
  10. C. E. M. Griffiths and H. L. Richards, “Psychological influences in psoriasis,” Clinical and Experimental Dermatology, vol. 26, no. 4, pp. 338–342, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. B. B. Davidovici, N. Sattar, P. C. Jörg et al., “Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions,” Journal of Investigative Dermatology, vol. 130, no. 7, pp. 1785–1796, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Koch, H. Baurecht, J. S. Ried et al., “Psoriasis and cardiometabolic traits: modest association but distinct genetic architectures,” Journal of Investigative Dermatology, vol. 135, no. 5, pp. 1283–1293, 2015. View at Publisher · View at Google Scholar
  13. P. Gisondi, A. Galvan, L. Idolazzi, and G. Girolomoni, “Management of moderate to severe psoriasis in patients with metabolic comorbidities,” Frontiers in Medicine, vol. 2, article 1, 2015. View at Publisher · View at Google Scholar
  14. N. Scheuing, C. Bayer, F. Best et al., “Is there a benefit to use calculated percent body fat or age- and gender-adjusted BMI-SDS(LMS) to predict risk factors for cardiovascular disease? A German/Austrian multicenter DPV-Wiss analysis on 42 048 type 2 diabetic patients,” Experimental and Clinical Endocrinology & Diabetes, vol. 121, no. 2, pp. 67–74, 2013. View at Publisher · View at Google Scholar
  15. C. Hemmelmann, S. Brose, M. Vens, J. Hebebrand, and A. Ziegler, “Percentiles of body mass index of 18–80-year-old German adults based on data from the second national nutrition survey,” Deutsche Medizinische Wochenschrift, vol. 135, no. 17, pp. 848–852, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and International Diabetes Federation, “Consensus statement on the worldwide standardisation of the HbA1c measurement,” Diabetologia, vol. 50, no. 10, pp. 2042–2043, 2007. View at Google Scholar
  17. E. R. Seaquist, J. Anderson, B. Childs et al., “Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society,” Diabetes Care, vol. 36, no. 5, pp. 1384–1395, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Gyldenløve, H. Storgaard, J. J. Holst, T. Vilsbøll, F. K. Knop, and L. Skov, “Patients with psoriasis are insulin resistant,” Journal of the American Academy of Dermatology, vol. 72, no. 4, pp. 599–605, 2015. View at Publisher · View at Google Scholar
  19. A. F. Pfeiffer and H. H. Klein, “The treatment of type 2 diabetes,” Deutsches Ärzteblatt International, vol. 111, no. 5, pp. 69–81, 2014. View at Google Scholar
  20. Deutsche Diabetes Gesellschaft, “Evidenzbasierte Nationale Versorgungsleitlinien,” 2014, http://www.deutsche-diabetes-gesellschaft.de/leitlinien/evidenzbasierte-leitlinien.html.
  21. M. Papelbaum, R. O. Moreira, W. Coutinho et al., “Depression, glycemic control and type 2 diabetes,” Diabetology and Metabolic Syndrome, vol. 3, no. 1, article 26, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. L. K. Richardson, L. E. Egede, M. Mueller, C. L. Echols, and M. Gebregziabher, “Longitudinal effects of depression on glycemic control in veterans with Type 2 diabetes,” General Hospital Psychiatry, vol. 30, no. 6, pp. 509–514, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Weigle and S. Mcbane, “Psoriasis,” The American Family Physician, vol. 87, no. 9, pp. 626–633, 2013. View at Google Scholar · View at Scopus
  24. A. Nast, W. H. Boehncke, U. Mrowietz et al., “S3—guidelines on the treatment of psoriasis vulgaris,” Journal der Deutschen Dermatologischen Gesellschaft, vol. 10, supplement 2, pp. S1–S95, 2012. View at Google Scholar
  25. D. H. van Raalte, D. M. Ouwens, and M. Diamant, “Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options?” European Journal of Clinical Investigation, vol. 39, no. 2, pp. 81–93, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. I. G. R. Baeta, B. Gontijo, F. V. Bittencourt, and E. M. A. Goulart, “Comorbidities and cardiovascular risk factors in patients with psoriasis,” Anais Brasileiros de Dermatologia, vol. 89, no. 5, pp. 735–744, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. I. Schäfer, S. J. Rustenbach, M. Radtke, J. Augustin, G. Glaeske, and M. Augustin, “Epidemiology of psoriasis in Germany—analysis of secondary health insurance data,” Gesundheitswesen, vol. 73, no. 5, pp. 308–313, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Mezuk, W. W. Eaton, S. Albrecht, and S. H. Golden, “Depression and type 2 diabetes over the lifespan: a meta-analysis,” Diabetes Care, vol. 31, no. 12, pp. 2383–2390, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. E. S. Brown, “Effects of glucocorticoids on mood, memory, and the hippocampus: treatment and preventive therapy,” Annals of the New York Academy of Sciences, vol. 1179, pp. 41–55, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. T. P. Warrington and J. M. Bostwick, “Psychiatric adverse effects of corticosteroids,” Mayo Clinic Proceedings, vol. 81, no. 10, pp. 1361–1367, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. N. N. Zammitt and B. M. Frier, “Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities,” Diabetes Care, vol. 28, no. 12, pp. 2948–2961, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Tschöpe, P. Bramlage, C. Binz, M. Krekler, E. Deeg, and A. K. Gitt, “Incidence and predictors of hypoglycaemia in type 2 diabetes—an analysis of the prospective DiaRegis registry,” BMC Endocrine Disorders, vol. 12, article 23, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. G. H. Murata, W. C. Duckworth, J. H. Shah, C. S. Wendel, and R. M. Hoffman, “Factors affecting hypoglycemia awareness in insulin-treated type 2 diabetes: the Diabetes Outcomes in Veterans Study (DOVES),” Diabetes Research and Clinical Practice, vol. 65, no. 1, pp. 61–67, 2004. View at Publisher · View at Google Scholar
  34. K. E. Nograles, R. D. Brasington, and A. M. Bowcock, “New insights into the pathogenesis and genetics of psoriatic arthritis,” Nature Clinical Practice Rheumatology, vol. 5, no. 2, pp. 83–91, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Antonelli, A. Delle Sedie, P. Fallahi et al., “High prevalence of thyroid autoimmunity and hypothyroidism in patients with psoriatic arthritis,” Journal of Rheumatology, vol. 33, no. 10, pp. 2026–2028, 2006. View at Google Scholar · View at Scopus
  36. U. Gul, M. Gonul, I. Kaya, and E. Aslan, “Autoimmune thyroid disorders in patients with psoriasis,” European Journal of Dermatology, vol. 19, no. 3, pp. 221–223, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. V. Witting, D. Bergis, D. Sadet, and K. Badenhoop, “Thyroid disease in insulin-treated patients with type 2 diabetes: a retrospective study,” Thyroid Research, vol. 7, no. 1, article 2, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. J. J. Díez, P. Sánchez, and P. Iglesias, “Prevalence of thyroid dysfunction in patients with type 2 diabetes,” Experimental and Clinical Endocrinology and Diabetes, vol. 119, no. 4, pp. 201–207, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. A.-R. M. Radaideh, M. K. Nusier, F. L. Amari et al., “Thyroid dysfunction in patients with type 2 diabetes mellitus in Jordan,” Saudi Medical Journal, vol. 25, no. 8, pp. 1046–1050, 2004. View at Google Scholar · View at Scopus
  40. D. LeRoith and D. H. Cohen, “Metabolic syndrome,” in Endotext South Dartmouth (MA), MDText.com, 2000. View at Google Scholar
  41. M. A. Alsufyani, A. K. Golant, and M. Lebwohl, “Psoriasis and the metabolic syndrome,” Dermatologic Therapy, vol. 23, no. 2, pp. 137–143, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. H. Takahashi and H. Iizuka, “Psoriasis and metabolic syndrome,” Journal of Dermatology, vol. 39, no. 3, pp. 212–218, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Takeshita, S. Wang, D. B. Shin et al., “Effect of psoriasis severity on hypertension control: a population-based study in the United Kingdom,” JAMA Dermatology, vol. 151, no. 2, pp. 161–169, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Stumvoll, B. J. Goldstein, and T. W. van Haeften, “Type 2 diabetes: principles of pathogenesis and therapy,” The Lancet, vol. 365, no. 9467, pp. 1333–1346, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. T. Cukierman-Yaffe, H. C. Gerstein, J. D. Williamson, and et al, “Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial,” Diabetes Care, vol. 32, no. 2, pp. 221–226, 2009. View at Google Scholar · View at Scopus
  46. B. Engin, Z. Kutlubay, G. Yardimci et al., “Evaluation of body composition parameters in patients with psoriasis,” International Journal of Dermatology, vol. 53, no. 12, pp. 1468–1473, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Prey, C. Paul, V. Bronsard et al., “Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies,” Journal of the European Academy of Dermatology and Venereology, vol. 24, supplement 2, pp. 23–30, 2010. View at Publisher · View at Google Scholar
  48. J. M. Chehade, M. Gladysz, and A. D. Mooradian, “Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management,” Drugs, vol. 73, no. 4, pp. 327–339, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. C. Willi, P. Bodenmann, W. A. Ghali, P. D. Faris, and J. Cornuz, “Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis,” The Journal of the American Medical Association, vol. 298, no. 22, pp. 2654–2664, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. M. D. Herron, M. Hinckley, M. S. Hoffman et al., “Impact of obesity and smoking on psoriasis presentation and management,” Archives of Dermatology, vol. 141, no. 12, pp. 1527–1534, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. A. R. Setty, G. Curhan, and H. K. Choi, “Smoking and the risk of psoriasis in women: Nurses' Health Study II,” American Journal of Medicine, vol. 120, no. 11, pp. 953–959, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. C. Fortes, S. Mastroeni, K. Leffondré et al., “Relationship between smoking and the clinical severity of psoriasis,” Archives of Dermatology, vol. 141, no. 12, pp. 1580–1584, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. Berufsverband der Deutschen Dermatologen, Unterversorgung kennt keine Grenzen, 2014, http://www.bvdd.info/jsp_public/cms2/index.jsp?did=6403.
  54. G. Hermann, A. Herbst, M. Schütt et al., “Association of physical activity with glycaemic control and cardiovascular risk profile in 65 666 people with type 2 diabetes from Germany and Austria,” Diabetic Medicine, vol. 31, no. 8, pp. 905–912, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. P. B. Wilson, K. A. Bohjanen, S. J. Ingraham, and A. S. Leon, “Psoriasis and physical activity: a review,” Journal of the European Academy of Dermatology and Venereology, vol. 26, no. 11, pp. 1345–1353, 2012. View at Publisher · View at Google Scholar · View at Scopus